Eli Lilly freezes salaries; Dr. Reddy's grows manufacturing; Pfizer spins off India animal health;

> This year Eli Lilly ($LLY) will freeze the salaries of most employees worldwide because of market challenges but did not say if there were manufacturing plant labor agreements that might exempt some employees from the penny-pinching. Story

> Generic drugmaker Dr. Reddy's Laboratories ($RDY), India's No. 2 drugmaker by sales, reports that its third-quarter global income from manufacturing services and pharmaceutical ingredients grew 12 percent to 5.56 billion rupees. Story

> Florida Biologix has said that its aseptic fill-and-finish facility for biopharmaceutical drug products meets European GMP requirements. Story

> The animal healthcare business of India's Pfizer Ltd. is being spun off from parent Pfizer ($PFE) for 4.4 billion rupees. Story

> OctoPlus, which develops and manufactures injectable pharmaceuticals, has signed a formulation development and manufacturing contract with Ferring Pharmaceuticals. Story

> Japan's Daiichi Sankyo, majority owner of troubled Indian generics maker Ranbaxy Laboratories ($RANBAXY.NS), is reportedly in talks to buy several smaller Indian drug companies. Story

> A lawsuit filed in New York alleges that Pfizer and Ranbaxy Laboratories schemed to delay generic Lipitor. Story

> GlaxoSmithKline ($GSK) will invest $65 million to expand its manufacturing and new drug development facilities near Melbourne, Australia. Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.